Mr. A ----Diffuse Large B-cell Lymphoma (DLBCL)

Mr. A, originally from India, a vibrant 66-year-old individual, embarked on his medical journey in April 2018. Following a biopsy of a mass in his left arm, and a comprehensive whole-body PET-CT scan, the diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) was rendered. This marked the commencement of a rigorous treatment regimen aimed at combatting the disease.

Undergoing a total of six cycles of the R-EPOCH chemotherapy regimen initially, Mr. A later transitioned to three cycles of the R-GDP regimen, followed by an additional two cycles of the same. This intensive chemotherapy regimen spanned from April 2018 to October 2019, a period characterized by perseverance and resilience in the face of adversity.

Despite the arduous treatment, a setback surfaced during the October 2019 PET-CT re-evaluation, revealing new metabolic irregularities in the right calcaneus area and the right distal femur. Undeterred, Mr. A, armed with the knowledge of BIOOCUS Medical Group's distinction as the foremost CAR-T center globally, sought out its expertise.

November 2019 marked a significant turning point as Mr. A embarked on a new phase of treatment under the care of our medical team. Comprehensive examinations revealed dim-positive CD19 and widely strong positive CD22, indicative of high residual tumor activity. In light of these findings, the decision was made to proceed with CD19+CD22 CAR-T cell therapy, a cutting-edge approach poised to tackle the persistent malignancy.

Following the infusion, Mr. A experienced a manageable degree 2 Cytokine Release Syndrome (CRS), swiftly recuperating thereafter. By January 2020, he was discharged, buoyed by promising results from the latest PET-CT scan showcasing tumor regression and a marked decline in metabolic activity.

Mr. A's journey serves as a beacon of hope, underscoring the transformative potential of advanced medical interventions in the realm of oncology. As he embarks on a long-term outpatient follow-up regimen, the focus remains on sustaining the newfound vitality and safeguarding against the resurgence of the disease.